Introduction
Hereditary spherocytosis (HS) is the most common variety of hereditary hemolytic disease among people of Northern European descent, with an estimated incidence of one case per 2000 to 4000 births. 1, 2 Several different genetic abnormalities result in the HS phenotype, all involving the structural components of the erythrocyte membrane. The most commonly affected proteins are ankyrin-1, a-spectrin, b-spectrin, band 3 and protein 4.2.
1,2 HS has been reported in Mexico 3 and one case of a 10-year-old Mexican child has been reported, 4 but we know of no reports of problematic neonatal hyperbilirubinemia in Mexican children associated with HS. Moreover, in the Intermountain Healthcare (Salt Lake City, UT, USA) databases, we have no HS cases in Hispanic neonates.
In an earlier report, we found a mean corpuscular hemoglobin concentration (MCHC) elevated to >36 to be a likely indicator of HS among jaundiced neonates. 5 We now report HS in late-preterm Hispanic twins, suspected on the basis of hyperbilirubinemia, reticulocytosis and elevated MCHC, and confirmed by finding spherocytosis and increased erythrocyte osmotic fragility. After making the diagnosis of HS, this diagnosis was also confirmed in a 4-year-old sibling and in the mother, both of whom had a history of jaundice and anemia.
Cases
Twin females were delivered at 35 2/7 weeks gestation to a G2, P 0,1,0,1, Spanish-speaking-only, 24-year-old married woman who emigrated from Southwestern Mexico (Michoacán) 4 years earlier.
Parents were non-consanguineous. 6 The delivery was a repeat cesarean section. The birth weights of Twin A and Twin B were 2060 and 1835 g, and Apgar scores were 7 and 9, and 7 and 8, respectively. The twins were admitted to the neonatal intensive care unit with minimal respiratory distress. Their initial blood hemoglobin concentrations were 14.5 and 16.2 g dl À1 , respectively. Six hours after birth, the total serum bilirubin in Twin A was 11.4 mg dl À1 and in Twin B was 12.1 mg dl À1 , and phototherapy was begun. Maternal blood type was A( þ ) and the antibody screen was negative. Phototherapy was discontinued after 24 h, but at 48 h the total serum bilirubin had risen to 16.9 mg dl À1 in Twin A and to 21.0 mg dl À1 in Twin B. Erythrocyte indices were obtained from blood samples run on a Beckman Coulter LH750 (Beckman Coulter, Fullerton, CA, USA). The MCHC of Twin A was 36.7 and of Twin B was 36.5 (95% reference range for neonates, 33.0 to 35.0 (ref. 7)). The mean corpuscular volume and mean corpuscular hemoglobin and all other complete blood count values were within the reference ranges for the neonates at Intermountain Healthcare, published previously. 8 The exception was the red cell distribution width, which was elevated in both: 20.3 and 22.4 (reference range 16.6 to 17.8). At 124 h after birth, the reticulocyte count on Twin A was 9.9% (367 000 ml À1 ) and immature reticulocyte fraction 0.54; on Twin B these measurements were 7.7% (285 000 ml À1 ) and 0.47, respectively.
Because of jaundice, reticulocytosis and elevated MCHC, blood smears and osmotic fragility tests were carried out (ARUP, Salt Lake City, UT, USA), which indicated HS. The hyperbilirubinemia persisted despite phototherapy, and after a total of 13 days the phototherapy was discontinued. At the time of hospital discharge to home, on day of life 15, the total serum bilirubin of Twin A was 12.0 mg dl À1 and of Twin B was 10.1 mg dl À1 . When the twins were diagnosed with HS, their father indicated that his 4-year-old daughter intermittently had yellow eyes, as did his wife. Laboratory evaluation on the 4-year-old and the mother revealed hemoglobin levels of 9.2 g dl À1 (4-year-old) and 9.3 g dl À1 (mother), MCHC 36.5 and 37.3, respectively, spherocytes on blood smear of both, and increased osmotic fragility.
As shown in the genetic pedigree chart (Figure 1 ), the mother of the twins (generation II) stated that her mother (generation I) was known to have anemia and intermittently yellow eyes all her life and died in Michoacán (Mexico) following childbirth. Her father (generation I) is alive and healthy. The mother of the twins has four full-siblings (generation II), all female, all born in Mexico and all still living in Mexico. One of her sisters is married and has one child, a daughter, thought to be well. One of the mother's sisters has chronic gall bladder disease. None of the family members in Mexico have been evaluated for hematological disorders.
Discussion
We recently reported the problem of HS among neonates with hyperbilirubinemia at the Intermountain Healthcare hospitals. 5 Intermountain Healthcare is a not-for-profit organization, operating 20 hospitals in Idaho and Utah. All cases of HS in that report were Caucasian non-Hispanic, and we have not considered HS to be a likely cause of neonatal hyperbilirubinemia among our Hispanic patients. However, we now suspect that we have been missing HS among our patients of Mexican ancestry. Thus, we now advise considering HS when evaluating the cause of neonatal Coombs negative hyperbilirubinemia, with an elevated MCHC, regardless of ancestry.
In our earlier report, we pointed out that an MCHC >36 g/dl can be a useful screening test for HS when a neonate has Coombs negative hemolytic jaundice. 5 After this simple screen, more definitive testing can be accomplished. For neonates with early jaundice, in addition to making the underlying diagnosis, considerable effort should be placed on bilirubin management so as to avoid bilirubin neurotoxicity. 9, 10 Neonatal hemolytic jaundice is a risk factor for kernicterus. 9, 10 When a neonate with hyperbilirubinemia is recognized to have a congenital hemolytic disease, careful anticipatory management is warranted so as to avoid kernicterus or 'near miss' kernicterus. Certain congenital hemolytic disorders tend to segregate according to ancestry. For instance, autosomal dominant forms of HS are reported more commonly among individuals of Northern European ancestry and autosomal recessive HS is more prevalent among Japanese populations.
1,2 A related disorder, South-East Asian ovalocytosis, is present in as many as 30% of people from Malaysia, New Guinea, Indonesia and the Philippines. 11 We speculate that the American Academy of Pediatrics' (Elk Grove Village, IL, USA) goal of preventing kernicterus 12 can be furthered by improving awareness of HS. Sometimes the diagnosis of HS in a neonate is suggested by the family history, as it is generally inherited in an autosomal dominant form. However, perhaps 25% of cases are de novo mutations or autosomal recessive forms, where the family history is not suggestive. Using the MCHC as a guide to the diagnosis, perhaps more patients with HS can be identified as neonates and anticipatory guidance can be provided regarding neonatal hyperbilirubinemia, chronic low-grade anemia and jaundice during childhood, and bilirubin pigment cholelithiasis in teens or young adults.
1,2 Moreover, as was the case in this report, making a diagnosis if HS is in a neonate can sometimes facilitate identifying the same disorder in other family members in whom jaundice and anemia have been long recognized but the specific diagnosis never made. 
